TriSalus Life Sciences, Inc.
TLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $133 | $224 | $297 | $309 |
| - Cash | $9 | $12 | $9 | $30 |
| + Debt | $24 | $2 | $2 | $1 |
| Enterprise Value | $148 | $213 | $290 | $279 |
| Revenue | $29 | $19 | $12 | $8 |
| % Growth | 59% | 49.3% | 47.6% | – |
| Gross Profit | $25 | $16 | $10 | $7 |
| % Margin | 86.1% | 85.9% | 81.8% | 85.8% |
| EBITDA | -$36 | -$59 | -$47 | -$24 |
| % Margin | -122.9% | -316.9% | -377.2% | -280.5% |
| Net Income | -$33 | -$59 | -$47 | -$29 |
| % Margin | -112.9% | -320.7% | -380.6% | -343.4% |
| EPS Diluted | -1.25 | -2.23 | -1.59 | -0.92 |
| % Growth | 43.9% | -40.3% | -72.8% | – |
| Operating Cash Flow | -$41 | -$51 | -$32 | -$23 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$41 | -$51 | -$33 | -$24 |